Etoposide Capsules

  • Respiratory and thoracic cancers

Etoposide Capsules Generic Name & Formulations

General Description

Etoposide 50mg; contain parabens.

Pharmacological Class

Topoisomerase inhibitor.

How Supplied

Contact supplier.

Etoposide Capsules Indications


Small cell lung cancer.

Etoposide Capsules Dosage and Administration


Round dose to nearest 50mg increment. Range: 70mg/m2 per day for 4 days to 100mg/m2 per day for 5 days. Repeat course every 3 to 4 weeks after recovery (esp myelosuppression). Renal impairment (CrCl ≤50mL/min): reduce dose (see literature). Consider dose reduction with existing myelosuppression due to previous radiation or chemotherapy.


Not recommended.

Etoposide Capsules Contraindications

Not Applicable

Etoposide Capsules Boxed Warnings

Not Applicable

Etoposide Capsules Warnings/Precautions


Monitor blood (esp CBC/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Pregnancy (Cat.D); nursing mothers: not recommended.

Etoposide Capsules Pharmacokinetics

See Literature

Etoposide Capsules Interactions


Potentiated by cyclosporine. Additive toxicity with radiation, other cytotoxic therapies.

Etoposide Capsules Adverse Reactions

Adverse Reactions

GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), alopecia, fever, infections, peripheral neurotoxicity; hypersensitivity reactions, acute leukemia (rare); others.

Etoposide Capsules Clinical Trials

See Literature

Etoposide Capsules Note


Formerly known under the brand name VePesid.

Etoposide Capsules Patient Counseling

See Literature